2-Tert-butylpyridine-3-carbonitrile | 1211523-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Tert-butylpyridine-3-carbonitrile
• CAS: 1211523-43-1
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: BSPCBCKSDYRTHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  丙烯醛 、 3-氨基-4,4-二甲基戊-2-烯腈 在 2-Amino-2-phenylethanethiol;hydrochloride 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以20%的产率得到2-Tert-butylpyridine-3-carbonitrile
  参考文献：
  名称：

  One-step synthesis of thiazolo[3,2-a]pyridines by a multicomponent reaction of β-enaminonitriles, α,β-unsaturated aldehydes, and 2-aminothiol hydrochlorides

  摘要：

  A wide library of 3,7,8,8a-tetrahydro-2H-thiazolo[3,2-a]pyridines has been prepared by simple heating in acetonitrile of beta-enaminonitriles, alpha,beta-unsaturated aldehydes and 2-aminothiol hydrochlorides. Chemical yields depend on the nature, hindrance, and position of the substituents. The scope, limitations, and stereocontrol associated to this three-component reaction have been studied in detail. In general, the diastereoinduction observed in the three new stereogenic centers generated in the pro-chiral alpha,beta-unsaturated aldehyde is low. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.02.051

文献信息

• N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20100298334A1

  公开（公告）日：2010-11-25

  The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及式I的N-(杂)芳基吡咯烷衍生物： 这些是JAK抑制剂，如选择性JAK1抑制剂，在治疗JAK相关疾病方面具有用处，例如炎症和自身免疫性疾病，以及癌症。
• PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BENAZET ALEXANDRE

  公开号：US20130079337A1

  公开（公告）日：2013-03-28

  The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim 1 , and also to the process for preparing them and to their therapeutic use.

  这项发明涉及与式（I）相对应的化合物，其中R1、R2和R3如权利要求1中所定义的，并且还涉及制备它们的过程以及它们的治疗用途。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE
  申请人：Samsung Display Co., Ltd.

  公开号：US20190312210A1

  公开（公告）日：2019-10-10

  An organic electroluminescence device includes a first electrode, a hole transport region on the first electrode, an emission layer on the hole transport region, an electron transport region on the emission layer, and a second electrode on the electron transport region, wherein the emission layer includes a polycyclic compound represented by Formula 1. In Formula 1, X 1 may be C, Si or Ge; and AC may be an electron acceptor.

  一种有机电致发光器件包括第一电极、位于第一电极上的空穴传输区域、位于空穴传输区域上的发射层、位于发射层上的电子传输区域和位于电子传输区域上的第二电极，其中发射层包括由式1表示的多环化合物。在式1中，X1 可以是C、Si或Ge; AC 可以是电子受体。
• Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
  申请人：Bursavich Matthew Gregory

  公开号：US20090325964A1

  公开（公告）日：2009-12-31

  The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.

  本发明涉及具有公式I的哌嗪代谢型谷氨酸受体5（mGluR5）负向变构调节剂： 其中，组成变量如本文所定义。本发明还涉及制备该化合物的方法，并涉及使用该化合物治疗疾病和障碍的方法，包括精神分裂症、偏执症、抑郁症、躁郁病和焦虑症。